Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2572-6. doi: 10.1128/AAC.02561-15. Print 2016 Apr.

Abstract

We assessed the pharmacokinetics and safety of solithromycin, a fluoroketolide antibiotic, in a phase 1, open-label, multicenter study of 13 adolescents with suspected or confirmed bacterial infections. On days 3 to 5, the mean (standard deviation) maximum plasma concentration and area under the concentration versus time curve from 0 to 24 h were 0.74 μg/ml (0.61 μg/ml) and 9.28 μg · h/ml (6.30 μg · h/ml), respectively. The exposure and safety in this small cohort of adolescents were comparable to those for adults. (This study has been registered at ClinicalTrials.gov under registration no. NCT01966055.).

Publication types

  • Clinical Trial, Phase I
  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics*
  • Area Under Curve
  • Bacterial Infections / blood
  • Bacterial Infections / drug therapy*
  • Child
  • Dried Blood Spot Testing
  • Female
  • Humans
  • Macrolides / blood
  • Macrolides / pharmacokinetics*
  • Male
  • Patient Safety
  • Triazoles / blood
  • Triazoles / pharmacokinetics*

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • Triazoles
  • solithromycin

Associated data

  • ClinicalTrials.gov/NCT01966055